No spin just facts. "Hitting our primary endpoint in both ITT and per protocol (PP) and secondary endpoint in PP with such short trial (14-week trial as compared to usually 24 to 32-week NASH trials) is a very strong statement of leronlimab’s potential. We believe we have a unique drug with tremendous opportunities.”
"The leronlimab 350 mg dose versus placebo comparison for the primary endpoint PDFF was statistically significant."
Recknor is one sharp dude. He devised both Open Label and Double Blinded trials. The Double Blinded study with 700 mg takes longer to assess, the results are being evaluated and will be disseminated immediately when known. By contrast the Open Label study done in contrast considers placebo effect. When both align with stat significance you know you have something strong to be excited about. Good job Recknor, good job leronlimab team.
Now, go figure the opportunity value when 5% of the world has a NASH problem and 20% advance to Cirrhosis. Wow! Who needs COVID??!!!
News 
Market Data 
Discover 
